厄洛替尼-话题@MedSci

#厄洛替尼#

39篇内容 | 2269人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1332073, encodeId=373f13320e38b, content=<a href='/topic/show?id=f19136915a9' target=_blank style='color:#2F92EE;'>#厄洛替尼#</a>, objectTitle=CLIN CANCER RES：Lumretuzumab联合西妥昔单抗或厄洛替尼治疗实体肿瘤, objectType=article, longId=113721, objectId=8ede113e21b9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8ede113e21b9, replyNumber=0, likeNumber=91, createdTime=2017-09-24, rootId=0, userName=ms306040998833292, userId=d3572500071, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8ede113e21b9, moduleTitle=CLIN CANCER RES：Lumretuzumab联合西妥昔单抗或厄洛替尼治疗实体肿瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8ede113e21b9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1332072, encodeId=77b313320e24b, content=<a href='/topic/show?id=f19136915a9' target=_blank style='color:#2F92EE;'>#厄洛替尼#</a>, objectTitle=JCO：吉西他滨+厄洛替尼辅助治疗胰腺导管腺癌，患者能否获益？, objectType=article, longId=110988, objectId=0e3c110988f4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0e3c110988f4, replyNumber=0, likeNumber=83, createdTime=2017-08-28, rootId=0, userName=ms306040998833292, userId=d3572500071, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0e3c110988f4, moduleTitle=JCO：吉西他滨+厄洛替尼辅助治疗胰腺导管腺癌，患者能否获益？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0e3c110988f4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1332071, encodeId=0b5013320e1f6, content=<a href='/topic/show?id=f19136915a9' target=_blank style='color:#2F92EE;'>#厄洛替尼#</a>, objectTitle=CLIN CANCER RES：Emibetuzumab联合厄洛替尼治疗晚期肿瘤, objectType=article, longId=96834, objectId=c41f9683457, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c41f9683457, replyNumber=0, likeNumber=85, createdTime=2017-04-24, rootId=0, userName=ms306040998833292, userId=d3572500071, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c41f9683457, moduleTitle=CLIN CANCER RES：Emibetuzumab联合厄洛替尼治疗晚期肿瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c41f9683457)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1332070, encodeId=fe4a13320e0c6, content=<a href='/topic/show?id=f19136915a9' target=_blank style='color:#2F92EE;'>#厄洛替尼#</a>, objectTitle=Plos One：Cherlerythrine与厄洛替尼联合治疗对非小细胞肺癌的作用如何？, objectType=article, longId=95901, objectId=f73e9590141, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f73e9590141, replyNumber=0, likeNumber=94, createdTime=2017-04-16, rootId=0, userName=ms306040998833292, userId=d3572500071, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f73e9590141, moduleTitle=Plos One：Cherlerythrine与厄洛替尼联合治疗对非小细胞肺癌的作用如何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f73e9590141)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1332069, encodeId=63b013320693a, content=<a href='/topic/show?id=f19136915a9' target=_blank style='color:#2F92EE;'>#厄洛替尼#</a>, objectTitle=JCO：吉非替尼vs.厄洛替尼的非劣效性研究, objectType=article, longId=65864, objectId=20536586403, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=20536586403, replyNumber=0, likeNumber=85, createdTime=2016-04-02, rootId=0, userName=ms306040998833292, userId=d3572500071, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=20536586403, moduleTitle=JCO：吉非替尼vs.厄洛替尼的非劣效性研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=20536586403)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1332068, encodeId=0217133206812, content=<a href='/topic/show?id=f19136915a9' target=_blank style='color:#2F92EE;'>#厄洛替尼#</a>, objectTitle=Ann Oncol：厄洛替尼对比化疗一线治疗对EGFR突变NSCLC患者总生存期影响 (OPTIMAL, CTONG-0802研究), objectType=article, longId=54327, objectId=0ab65432efa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0ab65432efa, replyNumber=0, likeNumber=0, createdTime=2015-08-03, rootId=0, userName=ms306040998833292, userId=d3572500071, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0ab65432efa, moduleTitle=Ann Oncol：厄洛替尼对比化疗一线治疗对EGFR突变NSCLC患者总生存期影响 (OPTIMAL, CTONG-0802研究), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0ab65432efa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1332067, encodeId=43ae133206e9e, content=<a href='/topic/show?id=f19136915a9' target=_blank style='color:#2F92EE;'>#厄洛替尼#</a>, objectTitle=JCO：厄洛替尼治疗EGFR突变肺癌患者有效, objectType=article, longId=50118, objectId=282d5011841, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=282d5011841, replyNumber=0, likeNumber=62, createdTime=2015-05-02, rootId=0, userName=ms306040998833292, userId=d3572500071, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=282d5011841, moduleTitle=JCO：厄洛替尼治疗EGFR突变肺癌患者有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=282d5011841)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1332066, encodeId=e7ee1332066f7, content=<a href='/topic/show?id=f19136915a9' target=_blank style='color:#2F92EE;'>#厄洛替尼#</a>, objectTitle=收官之战：Figitumumab不能提高厄洛替尼对非腺癌型NSCLC的疗效, objectType=article, longId=42705, objectId=f95f42e05f1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f95f42e05f1, replyNumber=0, likeNumber=44, createdTime=2014-11-19, rootId=0, userName=ms306040998833292, userId=d3572500071, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f95f42e05f1, moduleTitle=收官之战：Figitumumab不能提高厄洛替尼对非腺癌型NSCLC的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f95f42e05f1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1332065, encodeId=a6c6133206531, content=<a href='/topic/show?id=f19136915a9' target=_blank style='color:#2F92EE;'>#厄洛替尼#</a>, objectTitle=NICE再次更新厄洛替尼与吉非替尼指南, objectType=article, longId=38953, objectId=addc3895387, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=addc3895387, replyNumber=0, likeNumber=62, createdTime=2014-08-13, rootId=0, userName=ms306040998833292, userId=d3572500071, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=addc3895387, moduleTitle=NICE再次更新厄洛替尼与吉非替尼指南, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=addc3895387)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1332064, encodeId=fb6d133206409, content=<a href='/topic/show?id=f19136915a9' target=_blank style='color:#2F92EE;'>#厄洛替尼#</a>, objectTitle=厄洛替尼对EGFR突变的IA-IIIA期NSCLC术后维持治疗可能获益（SELECT研究）, objectType=article, longId=36430, objectId=2a7d3643000, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2a7d3643000, replyNumber=0, likeNumber=65, createdTime=2014-06-17, rootId=0, userName=ms306040998833292, userId=d3572500071, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2a7d3643000, moduleTitle=厄洛替尼对EGFR突变的IA-IIIA期NSCLC术后维持治疗可能获益（SELECT研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2a7d3643000)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1332063, encodeId=bcf71332063c4, content=<a href='/topic/show?id=f19136915a9' target=_blank style='color:#2F92EE;'>#厄洛替尼#</a>, objectTitle=厄洛替尼对完全切除的ⅠB-ⅢA期未区分EGFR突变的NSCLC肺癌并未显示获益（RADIANT研究）, objectType=article, longId=36429, objectId=9c3c36429bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9c3c36429bc, replyNumber=0, likeNumber=60, createdTime=2014-06-17, rootId=0, userName=ms306040998833292, userId=d3572500071, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9c3c36429bc, moduleTitle=厄洛替尼对完全切除的ⅠB-ⅢA期未区分EGFR突变的NSCLC肺癌并未显示获益（RADIANT研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9c3c36429bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1332062, encodeId=56671332062f5, content=<a href='/topic/show?id=f19136915a9' target=_blank style='color:#2F92EE;'>#厄洛替尼#</a>, objectTitle=ASCO 2014：EGFR阳性NSCLC厄洛替尼辅助治疗DFS无获益（RADIANT研究）, objectType=article, longId=35632, objectId=e39f3563261, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e39f3563261, replyNumber=0, likeNumber=66, createdTime=2014-06-02, rootId=0, userName=ms306040998833292, userId=d3572500071, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e39f3563261, moduleTitle=ASCO 2014：EGFR阳性NSCLC厄洛替尼辅助治疗DFS无获益（RADIANT研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e39f3563261)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1332061, encodeId=47911332061fa, content=<a href='/topic/show?id=f19136915a9' target=_blank style='color:#2F92EE;'>#厄洛替尼#</a>, objectTitle=Lancet Oncol：EGFR野生型NSCLC二线治疗：厄洛替尼不敌标准化疗（TAILOR研究）, objectType=article, longId=26016, objectId=35c626016f7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=35c626016f7, replyNumber=0, likeNumber=67, createdTime=2013-11-01, rootId=0, userName=ms306040998833292, userId=d3572500071, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=35c626016f7, moduleTitle=Lancet Oncol：EGFR野生型NSCLC二线治疗：厄洛替尼不敌标准化疗（TAILOR研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=35c626016f7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1332060, encodeId=b263133206061, content=<a href='/topic/show?id=f19136915a9' target=_blank style='color:#2F92EE;'>#厄洛替尼#</a>, objectTitle=JCO：不建议厄洛替尼联合贝伐单抗用于晚期NSCLC维持治疗, objectType=article, longId=25618, objectId=38b32561839, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=38b32561839, replyNumber=0, likeNumber=75, createdTime=2013-10-23, rootId=0, userName=ms306040998833292, userId=d3572500071, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=38b32561839, moduleTitle=JCO：不建议厄洛替尼联合贝伐单抗用于晚期NSCLC维持治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=38b32561839)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1332059, encodeId=a40e133205976, content=<a href='/topic/show?id=f19136915a9' target=_blank style='color:#2F92EE;'>#厄洛替尼#</a>, objectTitle=Lancet Oncol：化疗与厄洛替尼间插结合治疗晚期NSCLC效果良好, objectType=article, longId=21849, objectId=acb621849e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=acb621849e0, replyNumber=0, likeNumber=73, createdTime=2013-07-24, rootId=0, userName=ms306040998833292, userId=d3572500071, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=acb621849e0, moduleTitle=Lancet Oncol：化疗与厄洛替尼间插结合治疗晚期NSCLC效果良好, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=acb621849e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1332058, encodeId=206d1332058df, content=<a href='/topic/show?id=f19136915a9' target=_blank style='color:#2F92EE;'>#厄洛替尼#</a>, objectTitle=Lancet Oncol：化疗与厄洛替尼交替可使NSCLC患者受益（FASTACT-2研究）, objectType=article, longId=21382, objectId=275821382cd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=275821382cd, replyNumber=0, likeNumber=52, createdTime=2013-07-15, rootId=0, userName=ms306040998833292, userId=d3572500071, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=275821382cd, moduleTitle=Lancet Oncol：化疗与厄洛替尼交替可使NSCLC患者受益（FASTACT-2研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=275821382cd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1332057, encodeId=0614133205e01, content=<a href='/topic/show?id=f19136915a9' target=_blank style='color:#2F92EE;'>#厄洛替尼#</a>, objectTitle=ASCO2013：山东省肿瘤医院刘静发现厄洛替尼可用于预防III/IV期 NSCLC患者脑转移, objectType=article, longId=19009, objectId=b26119009cc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b26119009cc, replyNumber=0, likeNumber=69, createdTime=2013-05-22, rootId=0, userName=ms306040998833292, userId=d3572500071, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b26119009cc, moduleTitle=ASCO2013：山东省肿瘤医院刘静发现厄洛替尼可用于预防III/IV期 NSCLC患者脑转移, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b26119009cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1332056, encodeId=e5531332056c8, content=<a href='/topic/show?id=f19136915a9' target=_blank style='color:#2F92EE;'>#厄洛替尼#</a>, objectTitle=Ann Oncol：厄洛替尼可改善EGFR突变呈阳性的晚期NSCLC患者生活质量, objectType=article, longId=16121, objectId=a3fc16121f5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a3fc16121f5, replyNumber=0, likeNumber=72, createdTime=2013-03-17, rootId=0, userName=ms306040998833292, userId=d3572500071, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a3fc16121f5, moduleTitle=Ann Oncol：厄洛替尼可改善EGFR突变呈阳性的晚期NSCLC患者生活质量, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a3fc16121f5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1332055, encodeId=9c061332055d0, content=<a href='/topic/show?id=f19136915a9' target=_blank style='color:#2F92EE;'>#厄洛替尼#</a>, objectTitle=JCO：Dacomitinib优于厄洛替尼？, objectType=article, longId=12977, objectId=90b8129e7bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=90b8129e7bd, replyNumber=0, likeNumber=66, createdTime=2012-12-14, rootId=0, userName=ms306040998833292, userId=d3572500071, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=90b8129e7bd, moduleTitle=JCO：Dacomitinib优于厄洛替尼？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=90b8129e7bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1332054, encodeId=3ba9133205481, content=<a href='/topic/show?id=f19136915a9' target=_blank style='color:#2F92EE;'>#厄洛替尼#</a>, objectTitle=【ASCO 2012】厄洛替尼辅助治疗使EGFR突变NSCLC患者获益, objectType=article, longId=6938, objectId=f8c36938e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f8c36938e2, replyNumber=0, likeNumber=86, createdTime=2012-06-11, rootId=0, userName=ms306040998833292, userId=d3572500071, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f8c36938e2, moduleTitle=【ASCO 2012】厄洛替尼辅助治疗使EGFR突变NSCLC患者获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f8c36938e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

厄洛替尼

2020-05-29

ms306040998833292 (审核中...)

前往app查看评论内容

#厄洛替尼#

CLIN CANCER RES：Lumretuzumab联合西妥昔单抗或厄洛替尼治疗实体肿瘤

2017-09-24

ms306040998833292 (审核中...)

前往app查看评论内容

#厄洛替尼#

JCO：吉西他滨+厄洛替尼辅助治疗胰腺导管腺癌，患者能否获益？

2017-08-28

ms306040998833292 (审核中...)

前往app查看评论内容

#厄洛替尼#

CLIN CANCER RES：Emibetuzumab联合厄洛替尼治疗晚期肿瘤

2017-04-24

ms306040998833292 (审核中...)

前往app查看评论内容

#厄洛替尼#

Plos One：Cherlerythrine与厄洛替尼联合治疗对非小细胞肺癌的作用如何？

2017-04-16

ms306040998833292 (审核中...)

前往app查看评论内容

#厄洛替尼#

JCO：吉非替尼vs.厄洛替尼的非劣效性研究

2016-04-02

ms306040998833292 (审核中...)

前往app查看评论内容

#厄洛替尼#

Ann Oncol：厄洛替尼对比化疗一线治疗对EGFR突变NSCLC患者总生存期影响 (OPTIMAL, CTONG-0802研究)

2015-08-03

ms306040998833292 (审核中...)

前往app查看评论内容

#厄洛替尼#

JCO：厄洛替尼治疗EGFR突变肺癌患者有效

2015-05-02

ms306040998833292 (审核中...)

前往app查看评论内容

#厄洛替尼#

收官之战：Figitumumab不能提高厄洛替尼对非腺癌型NSCLC的疗效

2014-11-19

ms306040998833292 (审核中...)

前往app查看评论内容

#厄洛替尼#

NICE再次更新厄洛替尼与吉非替尼指南

2014-08-13

ms306040998833292 (审核中...)

前往app查看评论内容

#厄洛替尼#

厄洛替尼对EGFR突变的IA-IIIA期NSCLC术后维持治疗可能获益（SELECT研究）

2014-06-17

ms306040998833292 (审核中...)

前往app查看评论内容

#厄洛替尼#

厄洛替尼对完全切除的ⅠB-ⅢA期未区分EGFR突变的NSCLC肺癌并未显示获益（RADIANT研究）

2014-06-17

ms306040998833292 (审核中...)

前往app查看评论内容

#厄洛替尼#

ASCO 2014：EGFR阳性NSCLC厄洛替尼辅助治疗DFS无获益（RADIANT研究）

2014-06-02

ms306040998833292 (审核中...)

前往app查看评论内容

#厄洛替尼#

Lancet Oncol：EGFR野生型NSCLC二线治疗：厄洛替尼不敌标准化疗（TAILOR研究）

2013-11-01

ms306040998833292 (审核中...)

前往app查看评论内容

#厄洛替尼#

JCO：不建议厄洛替尼联合贝伐单抗用于晚期NSCLC维持治疗

2013-10-23

ms306040998833292 (审核中...)

前往app查看评论内容

#厄洛替尼#

Lancet Oncol：化疗与厄洛替尼间插结合治疗晚期NSCLC效果良好

2013-07-24

ms306040998833292 (审核中...)

前往app查看评论内容

#厄洛替尼#

Lancet Oncol：化疗与厄洛替尼交替可使NSCLC患者受益（FASTACT-2研究）

2013-07-15

ms306040998833292 (审核中...)

前往app查看评论内容

#厄洛替尼#

ASCO2013：山东省肿瘤医院刘静发现厄洛替尼可用于预防III/IV期 NSCLC患者脑转移

2013-05-22

ms306040998833292 (审核中...)

前往app查看评论内容

#厄洛替尼#

Ann Oncol：厄洛替尼可改善EGFR突变呈阳性的晚期NSCLC患者生活质量

2013-03-17

ms306040998833292 (审核中...)

前往app查看评论内容

#厄洛替尼#

JCO：Dacomitinib优于厄洛替尼？

2012-12-14

ms306040998833292 (审核中...)

前往app查看评论内容

#厄洛替尼#

【ASCO 2012】厄洛替尼辅助治疗使EGFR突变NSCLC患者获益

2012-06-11

科室
- - 订阅+
  - 更多科室
工具
服务